$ News

MYD: The Wrong End Of The Muni Market For Me

RFMZ: Successful Swap, Remains An Interesting Choice

UnitedHealth update ‘not the end’ for Myriad’s GeneSight, says Raymond James

Piper says Myriad appears to be trading down on GeneSight coverage change

Myriad weakness due to UnitedHealth coverage update, says Stephens

Scotiabank Keeps Their Buy Rating on Myriad Genetics (MYGN)

Steady Growth and Market Stability Justify Hold Rating for Myriad Genetics

Myriad Genetics: Strategic Growth and Raised Price Target Reinforce Outperform Rating

Myriad Genetics: A Buy Rating Amid Reaffirmed Strategy and Growth Potential

Myriad Genetics: Assessing Sustainability of Revenue Growth Amid Market Challenges

Myriad Genetics: A Promising Outlook on Growth and Market Confidence

BlackRock MuniYield raises monthly dividend by 3.8% to $0.0545/share

Maintained Buy Rating on Myriad Genetics Amid GeneSight Study Discontinuation

BlackRock MuniYield declares $0.0525 dividend

Myriad Genetics Reports GeneSight Testing Study Progress

Scotiabank Remains a Buy on Myriad Genetics (MYGN)

Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)

Myriad Genetics: A Strong Buy on Transformation Success and Solid Growth Prospects

Myriad Genetics (MYGN) Receives a Hold from Piper Sandler

TD Cowen Keeps Their Hold Rating on Myriad Genetics (MYGN)